Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead drug candidate for multiple sclerosis, Lucid-MS, toward a Phase 2 clinical trial while simultaneously commercializing its alcohol-metabolism product unbuzzd, according to a recent BioMedWire Podcast featuring Executive Co-Chairman and Co-Founder Anthony Durkacz. The dual approach highlights the company's strategy of combining clinical-stage pharmaceutical development with immediate commercial opportunities across neurodegenerative, metabolic and alcohol-misuse conditions.
Durkacz outlined the development strategy for Lucid-MS, which aims to address mobility damage associated with multiple sclerosis. The company has filed an investigational new drug application for a Phase 2 trial, which could represent the first administration of Lucid-MS to human MS patients. Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Multiple sclerosis affects approximately 2.8 million people worldwide, and current treatments often focus on managing symptoms rather than reversing damage, underscoring the potential impact of a therapy that could repair myelin.
In addition to its clinical pipeline, Quantum BioPharma is generating revenue through unbuzzd, a commercially available product designed to accelerate alcohol metabolism. The company spun out the over-the-counter version to Unbuzzd Wellness Inc. (UWI), led by industry veterans, while retaining a 19.84% ownership stake as of March 31, 2026, in UWI. The agreement includes royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The combination of a late-stage clinical candidate and a revenue-generating consumer product provides Quantum BioPharma with a diversified business model that could reduce reliance on external funding while advancing its pipeline. The company's focus on neurodegenerative and metabolic disorders, as well as alcohol misuse, positions it in multiple high-need therapeutic areas. For the pharmaceutical industry, the success of Lucid-MS could represent a paradigm shift in MS treatment, moving from symptom management to disease modification by targeting myelin repair. For investors, the unbuzzd revenue stream offers a near-term return while awaiting clinical milestones.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for challenging conditions. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. More information about the company's recent developments can be found in its newsroom at https://ibn.fm/QNTM. The BioMedWire podcast episode featuring Durkacz is available at https://ibn.fm/IWnPQ.
